New immunotherapy cocktail aims to tackle tough lung cancer
NCT ID NCT07245446
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests whether adding extra immunotherapy drugs to standard chemotherapy can better control extensive-stage small cell lung cancer. About 180 adults who have not had prior treatment will be randomly assigned to one of three groups, all receiving the immunotherapy ivonescimab plus chemo, with some also getting cadonilimab or AK117. The goal is to see which combination shrinks tumors most safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivonescimab (an immunotherapy drug) combined with chemotherapy (etoposide and carboplatin) and optionally cadonilimab or AK117
What this could lead to
If successful, this could offer a new first-line treatment option that shrinks tumors and controls extensive-stage small cell lung cancer for longer.
What could go wrong
This is an early Phase 2 trial with only 180 participants, so results may not apply to everyone. Side effects from combining multiple drugs could be significant, and the added drugs may not improve outcomes over standard chemo-immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100020, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanghai Pulmonary Hospital Affiliated to Tongji University
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITINGXi'an, Shaanxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact